CAR-T plus stem cell transplant for hard-to-treat multiple myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests combining CAR-T cell therapy with a donor stem cell transplant for multiple myeloma that has come back or not responded to treatment. It aims to see if this approach can help when other treatments have failed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have multiple myeloma that has relapsed (come back) or is refractory (did not respond to treatment).
- Your liver and kidney function are within safe limits.
- You are able to perform daily activities (Karnofsky score over 50%).
- You have not had success with a prior stem cell transplant, or you are not eligible for one.
- You are willing to receive CAR-T cell therapy and can tolerate the blood collection process.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving BCMA-targeting CAR-T cells after a stem cell transplant can help treat newly diagnosed multiple myeloma. It is for people who are healthy enough for both procedures.
This study combines a stem cell transplant with a special immune therapy (CAR-T) to treat multiple myeloma that is very aggressive and has not responded well to initial treatments. The goal is to see if this combination can better control the cancer.
This trial tests a new type of immunotherapy called Multi-CAR T cells for people with multiple myeloma that has come back or not responded to other treatments. It aims to see if these specially engineered cells can better fight the cancer.
This trial tests a new kind of CAR-T cell therapy (called APRIL-BAFF-Bicephali CAR-T) for people with multiple myeloma that has come back or not responded to treatment. It aims to see if this therapy is safe and can help when other treatments have stopped working.
This trial tests a new CAR-T cell therapy that targets FcRL5 on myeloma cells. It's for people whose myeloma has come back or stopped responding to other treatments, including stem cell transplant.
This trial tests a new type of immunotherapy called CAR-T cells given as part of an early treatment plan for multiple myeloma or plasmacytoma. The goal is to see if this approach can help achieve a deep remission, especially after a stem cell transplant.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.